Pharmacognostical and Pharmacological Evaluation of Atropa belladonna: An Overview

Abstract

Medicinal plants are always having significant roles for preventing and treating different diseases. Solanaceae is among one of the family member for associating this one. Atropa belladonna is one of them. These plants were discovered centuries ago. Besides this plants are used for ethno-botanical purposes. These plants are rich sources of lots of chemical cum active constituents like tropane alkaloids such as hyoscyamine, atropine, and scopolamine. Tropane alkaloids are used as antimuscarinic or anticholinergic agents as they inhibit the production of acetyl choline. This review article provides detail knowledge of Belladonna including its history, chemical properties, pharmacological actions, etc.

Introduction

Atropa belladonna, commonly known as deadly nightshade or belladonna, belongs to the Solanaceae family. It is a highly toxic plant containing potent tropane alkaloids such as atropine, scopolamine, and hyoscyamine, which can cause symptoms like delirium and hallucination. The name derives from the Greek goddess Atropos and the Italian term meaning "beautiful lady."

Botanical Description

• Roots: Fleshy, brown or pale yellow outside, whitish inside.

• Stem: Soft, upright, changing from green to dark purple.

• Leaves: Brittle, stalked, dull green.

• Flowers: Bell-shaped, changing color from purple to yellowish-brown.

• Fruits: Shiny black fleshy berries containing many seeds.

History & Distribution

• Originated in Greece, used historically in medicinal formulations.

• Found mainly in dry, uncultivated regions of Europe, West Asia, North Africa, Himalayas, and parts of North America.

• Prefers well-drained, lime-rich soil and partial shade.

Cultivation & Collection

• Best grown in well-drained, calcareous soil with sunlight or light shade.

• Alkaloid content varies with atmospheric conditions.

• Harvesting starts after 4 years; drying is crucial to preserve alkaloids.

Toxicity

• Toxic throughout the plant, especially in berries.

• Poisoning affects central and peripheral nervous systems.

Chemical Constituents

• Contains multiple alkaloids including atropine, hyoscyamine, and scopolamine.

• Other components include various acids, alkaloids, and flavonoids.

Key Alkaloids

• Atropine: Used as an analgesic, antispasmodic, and for dilating pupils; increases heart rate.

• Hyoscyamine: Relieves muscle spasms, reduces secretions; causes side effects like dry mouth and blurred vision.

• Scopolamine: Treats motion sickness, abdominal pain, and induces drowsiness.

Pharmacological Actions & Uses

• Blocks parasympathetic nervous system receptors, affecting heart, eyes, GI tract, lungs, smooth muscles, and sweat glands.

• Therapeutically used for motion sickness, respiratory disorders, myocardial infarction, eye examinations, excessive salivation, peptic ulcers, and urinary infections.

Adverse Effects

• Can cause photophobia, insomnia, dizziness, pupil dilation, leukocytosis, allergic reactions, high fever, heart irregularities, and coordination problems.

Conclusion

Atropa belladonna is considered profoundly important in our modern pharmacological history as well as the ancient one because of its powerful anti-cholinergic effects. The key bioactive compounds in this plant-atropine, scopolamine, and hyoscyamine block acetylcholine at the muscarinic receptor, and thus elicit a wide range of physiological impacts, for instance, pupil dilation, tachycardia, decreased secretions, and smooth muscle relaxation. Such properties have been exploited extensively in medicine for treating bradycardia, motion sickness, and gastrointestinal conditions, among others, where muscarinic blockade is reasonably therapeutically favorable. However, despite being significantly vital, the use of the plant is always erratic in therapeutically endeavors. The narrow therapeutic window of alkaloids found in Atropa belladonna demands extremely meticulous dosing to avoid administration that may provoke severe toxicity, variable from simple confusion and hallucinations to seizures or even death. Such is the toxic risk that, for some time now, a shift has been made toward synthetic analogs and more precisely controlled breeding variants of these compounds, such as atropine sulfate and scopolamine patches that offer all the branched benefits of anti-cholinergic activity and reliability in safety profiles. The historical and contemporary use of Atropa belladonna exemplifies a dual problem of many plant-based medicines in that they provide a strong potential with equally significant dangers on the other side when not managed properly. Further research in more selective muscarinic receptor antagonists is ongoing as is the development of safer formulations, highlighting the need for careful balance in maximizing effectiveness versus minimizing the adverse effects. Ultimately, while Atropa belladonna remains a tool of great utility in medicine, its application must always be dealt with sober caution and precision.

References

[1] Kokate CK, Purohit AP, Gokhale SB: Pharmacognosy. Volume I & II. Nirali Prakashan; 47th Edition: 2012:15.44-15.47 [2] Evans WC. Trease and Evans Pharmacognosy. Saunders Elsevier. 2009; 16:365-367. [3] Kraemer H, Kilmer FB, Johnson and Johnson,Inc, Johnson & Johnson. Belladonna. Johnson & Johnson Publisher, New York, USA; 1894:2-72 [4] Datta K. An updated overview on Atropa belladonna L. The International Research Journal of Pharmacy. 2011; 2(11):1-7. [5] Ouasti I, Fakchich J, Bussmann RW, Jan HA, Elachouri M. Atropa Belladonna L. Solanaceae. In Ethnobotany of Northern Africa and Levant. 2024; 11:481-486. [6] Bhattacharya S, Chakraborty S, Roy A, Bhattacharjee A. Solanaceae Containing Medicinal Plants and Its Importance: An Overview. International Journal of Pharmaceutical Sciences Review and Research. 2023; 83(2): 106-112. [7] Ott B. Atropa belladonna. The Journal of the American Pharmaceutical Association.1915; 4(2):234-238. [8] Nikandish M, Nikandish M. Exploring the History, Uses, and Dangers of Belladonna: Unveiling the Mysteries of the Deadly Nightshade. ESI Preprints. 2024; 27:544-550. [9] Kizi KS. Atropa belladonna, deadly nightshade and its peculiarities. International Journal of Medical Science and Public Health Research. 2022; 3(4):13-17. [10] Campbell EA. Don\'t Say It with Nightshades: Sentimental Botany and the Natural History of Atropa Belladonna. Victorian Literature and Culture. 2007; 35(2):607-15. [11] Butcher RW. Atropa Belladonna L. Journal of Ecology. 1947; 34(2):345-53. [12] Yang DZ, Zhang ZY, Lu AM, Sun K, LIUc JQ. Floral organogenesis and development of two taxa of the Solanaceae--Anisodustanguticus and Atropa belladonna. Israel journal of plant sciences. 2002; 50(2):127-34. [13] Copete E, Copete MA, Martínez-Duro E, Santiago A, Ferrandis P, Herranz JM. Plant Production Protocols from Seeds of Threatened Atropa baetica and Widespread A. belladonna, Both Rich in Alkaloids. Life. 2023; 13(11):2181. [14] Nakanishi F, Sasaki K, Shimomura K. Kinetics of littorine content in various developing stages of regenerates of Atropa belladonna. Plant cell reports. 2000; 19:1021-6. [15] Kamada H, Okamura N, Satake M, Harada H, Shimomura K. Alkaloid production by hairy root cultures in Atropa belladonna. Plant cell reports. 1986; 5:239-42. [16] Whatmough WA. THE CULTIVATION AND COLLECTION OF MEDICINAL PLANTS IN ENGLAND. Journal of the Royal Society of Arts. 1914;62(3232):995-1003 [17] Ali RM. Role of putrescine in salt tolerance of Atropa belladonna plant. Plant Science. 2000; 152 (2):173-9. [18] Zahiriddinov II. TIMES FOR CARRYING OUT AGROTECHNICAL MEASURES TO INCREASE THE YIELD OF ATROPA BELLADONNA L. Innovative Development in Educational Activities. 2024; 3(13):99-103. [19] Ramjan KA, Williams AJ, Isbister GK, Elliott EJ. ‘Red as a beet and blind as a bat’Anticholinergic delirium in adolescents: lessons for the paediatrician. Journal of paediatrics and child health. 2007; 43(11):779-80. [20] Udaykumar P. Medical Pharmacology. 1st ed. [eBook]. New Delhi: CBS Publishers & Distributors; 2019 :87-93 [21] Jiang X, Chi J, Xu EP, Wang ZM, Dai LP. Chemical constituents from Atropa belladonna roots. Chemistry of Natural Compounds. 2023; 59(3):556-8. [22] Lee KT, Yamakawa T, Kodama T, Shimomura K. Effects of chemicals on alkaloid production by transformed roots of belladonna. Phytochemistry. 1998; 49(8):2343-7. [23] Danaie E, Masoudi S, Masnabadi N. Chemical composition analysis of atropa belladonna grown in Iran and evaluation of antibacterial properties of extract-loaded nanofibers. Iranian Journal of Pharmaceutical Research: IJPR. 2023; 22(1):1-14. [24] Schermeister LJ, Crane FA, Voigt RF. Nitrogenous constituents of Atropa belladonna L. grown on different sources of externally supplied nitrogen. Journal of the American Pharmaceutical Association (Scientific Ed.). 1960; 49(11):698-705. [25] Alsaedi NJ, Jawad LK, Mahdi SA. Medicinal importance of Atropa belladonna plant (tropane alkaloids). Kirkuk University Journal for Agricultural Sciences. 2023; 14(3):88-97. [26] Lakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, Shevyrin VA, Wappler-Guzzetta EA, Kalueff AV. Dark classics in chemical neuroscience: atropine, scopolamine, and other anticholinergic deliriant hallucinogens. ACS chemical neuroscience. 2018; 10(5):2144-59. [27] Bedrossian RH. The effect of atropine on myopia. Ophthalmology. 1979; 86(5):713-7. [28] Albanus L. Central and peripheral effects of anticholinergic compounds. ActaPharmacologicaetToxicologica. 1970; 28(4):305-26. [29] Kanto J, Klotz U. Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate. Actaanaesthesiologicascandinavica. 1988; 32(2):69-78. [30] Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006; 113(12):2285-91. [31] Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L. Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA ophthalmology. 2017; 135(6):624-30. [32] Marine JE, Watanabe MA, Smith TW, Monahan KM. Effect of atropine on heart rate turbulence. American Journal of Cardiology. 2002; 89(6):767-9. [33] Patocka J, Jelinkova R. Atropine and atropine-like substances usable in warfare. Mil. Med. Sci. Lett. 2017; 86(2):58-69. [34] Kaduk JA, Gindhart AM, Blanton TN. Crystal structure of atropine sulfate monohydrate, (C17H24NO3) 2 (SO4) • (H2O). Powder Diffraction. 2019; 34(4):389-95. [35] Du GH, Fang LH, Wang JH, Du GH. Atropine. Natural Small Molecule Drugs from Plants. 2018:181-6. [36] Nachod FC, Lands AM. SECTION OF PHYSICS AND CHEMISTRY*: THE RELATIONSHIP BETWEEN CHEMICAL STRUCTURE AND BIOLOGICAL ACTIVITY OF COMPOUNDS WITH ATROPINE?LIKE ACTIVITY. Transactions of the New York Academy of Sciences. 1953; 16(1 Series II):2-13. [37] Werner LF. ANALOGUES OF ATROPINE AND HOMATROPINE. Journal of the American Chemical Society. 1918; 40(4):669-74. [38] Alagarsamy V. Textbook of Medicinal Chemistry – Volume I. 1st Ed. New Delhi: Elsevier; 2010:419-43 [39] Shaheen NJ, Robertson DJ, Crosby MA, Furs SJ, May DT, Harlan WR, Grimm IS, Isaacs KL, Bozymski EM. Hyoscyamine as a pharmacological adjunct in colonoscopy: a randomized, double blinded, placeb o-controlled trial. The American journal of gastroenterology. 1999; 94(10):2905-8. [40] Browne T. Therapeutic Effects of Hyoscyamine. British Medical Journal. 1882; 2(1143):1030. [41] Hashimoto T, Yamada Y, Leete E. Species-dependent biosynthesis of hyoscyamine. Journal of the American Chemical Society. 1989; 111(3):1141-2. [42] Ullrich SF, Hagels H, Kayser O. Scopolamine: a journey from the field to clinics. Phytochemistry Reviews. 2017; 16:333-53. [43] Bajo R, Pusil S, Lopez ME, Canuet L, Pereda E, Osipova D, Maestú F, Pekkonen E. Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer’s disease. Scientific reports. 2015; 5(1):9748. [44] Weinstein H, Srebrenik S, Maayani S, Sokolovsky M. A theoretical model study of the comparative effectiveness of atropine and scopolamine action in the central nervous system. Journal of Theoretical Biology. 1977; 64(2):295-309. [45] Zufall CJ, Burlage A. Vein islets as means of identifying drugs and detecting adulterants. Journal of the American Pharmaceutical Association. 1932; 21(4):330-3. [46] Menthe S, Menthe R. Substitution and adulteration-past and present. Ayushdhara. 2017; 4(2):1118-24. [47] Lancaster HM, Davidson AL. COMMERCIAL PHARMACEUTICAL PREPARATIONS: 3.-BELLADONNA LEAVES. Canadian Medical Association Journal. 1927; 17(10 Pt 1):1187. [48] Khanna KL, Atal CK. PhytolaccaacinosaRoxb, an adulterant of Indian belladonna. Journal of Pharmacy and Pharmacology. 1960; 12(1):365-71. [49] Goodman and gillman’sThe Pharmacological Basis of Therapeutics. McGraw-Hill Education. 2018; 13:149-160. [50] Rang HP, Ritter JM, Flower R, Henderson G, MacEwan D, Loke YK. Rang and Dale Pharmacology. Elsevier. 2018; 9:175-185. [51] Tripathi KD. Essentials of medical pharmacology. Jaypee Brothers medical publishers; 2018; 8; 113-118. [52] Ketchum JS, Sidell FR, Crowell Jr EB, Aghajanian GK, Hayes Jr AH. Atropine, scopolamine, and ditran: Comparative pharmacology and antagonists in man. Psychopharmacologia. 1973; 28(2):121-45. [53] Rajput H. Effects of Atropa belladonna as an anti-cholinergic. Natural Products Chemistry & Research. 2013; 1(1):1-2. [54] Weissler AM, Leonard JJ, Warren JV. Effects of posture and atropine on the cardiac output. The Journal of Clinical Investigation. 1957; 36(12):1656-62. [55] Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 1. American Heart Journal. 1980; 100(1):119-27. [56] Marine JE, Watanabe MA, Smith TW, Monahan KM. Effect of atropine on heart rate turbulence. American Journal of Cardiology. 2002; 89(6):767-9. [57] Nalefski LA, Brown CF. Action of atropine on the cardiovascular system in normal persons. AMA Archives of Internal Medicine. 1950; 86(6):898-907. [58] Hoffer A. Effect of atropine on blood pressure of patients with mental and emotional disease. AMA Archives of Neurology & Psychiatry. 1954; 71(1):80-6. [59] Knoebel SB, McHenry PL, Phillips JF, Widlansky S. Atropine-inducedcardioacceleration and myocardial blood flow in subjects with and without coronary artery disease. The American Journal of Cardiology. 1974; 33(3):327-32. [60] Conrad KA. Effects of atropine on diastolic time. Circulation. 1981; 63(2):371-7. [61] Rosner V, Kepes ER, Foldes FF. The effects of atropine and neostigmine on heart rate and rhythm. British Journal of Anaesthesia. 1971; 43(11):1066-74. [62] McBrien NA, Stell WK, Carr B. How does atropine exert its anti?myopia effects? Ophthalmic and Physiological Optics. 2013; 33(3):373-8. [63] LEOPOLD IH, COMROE JH. Effect of intramuscular administration of morphine, atropine, scopolamine and neostigmine on the human eye. Archives of Ophthalmology. 1948 1; 40(3):285-90. [64] SCHWAHN HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Visual neuroscience. 2000; 17(2):165-76. [65] Feldman M, Walsh JH. Acid inhibition of sham feeding-stimulated gastrin release and gastric acid secretion: effect of atropine. Gastroenterology. 1980; 78(4):772-6. [66] Kolbel CB, Singer MV, Mohle T, Heinzel C, Eysselein V, Goebell H. Action of intravenous ethanol and atropine on the secretion of gastric acid, pancreatic enzymes, and bile acids and the motility of the upper gastrointestinal tract in nonalcoholic humans. Pancreas. 1986; 1(3):211-8. [67] Lind JF, Crispin JS, McIver DK. The effect of atropine on the gastroesophageal sphincter. Canadian journal of physiology and pharmacology. 1968; 46(2):233-8. [68] Burger DM, Wiestner T, Hubler M, Binder H, Keiser M, Arnold S. Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers. Journal of Veterinary Medicine Series A. 2006; 53(2):97-107. [69] Mubaslat O, Lambert T. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial. Psychopharmacology. 2020; 237:2905-15. [70] Ekström J, Månsson B, Tobin G, Garrett JR, Thulin A. Atropine?resistant secretion of parotid saliva on stimulation of the auriculo?temporal nerve. Actaphysiologicascandinavica. 1983; 119(4):445-9. [71] Casterline CL, Evans R, Ward GW. The effect of atropine and albuterol aerosols on the human bronchial response to histamine. Journal of Allergy and Clinical Immunology. 1976; 58(5):607-13. [72] Islam MS, Melville GN, Ulmer WT. Role of atropine in antagonizing the effect of 5-hydroxytryptamine (5-HT) on bronchial and pulmonary vascular systems. Respiration. 1974; 31(1):47-59. [73] Neuhaus A, Markowitz D, Rotman HH, Weg JG. The effects of fiberoptic bronchoscopy with and without atropine premedication on pulmonary function in humans. The Annals of thoracic surgery. 1978; 25(5):393-8. [74] Marini JJ, Lakshminarayan S. The effect of atropine inhalation in “irreversible” chronic bronchitis. Chest. 1980; 77(5):591-6. [75] Cuthbert AW. Some effects of atropine on smooth muscle. British Journal of Pharmacology and Chemotherapy. 1963; 21(2):285-94. [76] Christensen J, Lund GF. Atropine excitation of esophageal smooth muscle. The Journal of Pharmacology and Experimental Therapeutics. 1968;163(2):287-9 [77] Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. The Journal of urology. 1999; 162(5):1833-9. [78] Sjögren C, Andersson KE, Husted S, Mattiasson A, Moller-Madsen B. Atropine resistance of transmurally stimulated isolated human bladder muscle. The Journal of urology. 1982; 128(6):1368-71. [79] Gibi?ski K, Giec L, Zmudzi?ski J, Dosiak J, Waclawczyk J. Transcutaneous inhibition of sweat gland function by atropine. Journal of Applied Physiology. 1973; 34(6):850-2. [80] Cummings EG, Craig FN. Influence of the rate of sweating on the inhibitory dose of atropine. Journal of Applied Physiology. 1967; 22(4):648-54. [81] Kolka MA, Stephenson LA. Cutaneous blood flow and local sweating after systemic atropine administration. PflügersArchiv-European Journal of Physiology. 1987; 410(4):524-9. [82] Gould MN, Yatvin MB. Atropine-caused central nervous system interference with radiation-induced learned and unlearned behaviours. International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine. 1973; 24(5):463-8. [83] Brocks DR. Anticholinergic drugs used in Parkinson\'s disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999; 2(2):39-46. [84] Protus BM, Grauer PA, Kimbrel JM. Evaluation of atropine 1% ophthalmic solution administered sublingually for the management of terminal respiratory secretions. American Journal of Hospice and Palliative Medicine®. 2013; 30(4):388-92. [85] Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. The American Journal of Medicine Supplements. 2004; 117(12):24-32. [86] Scheinman MM, Thorburn DA, Abbott JA. Use of atropine in patients with acute myocardial infarction and sinus bradycardia. Circulation. 1975; 52(4):627-33. [87] Coon GA, Clinton JE, Ruiz E. Use of atropine for brady-asystolicprehospital cardiac arrest. Annals of emergency medicine. 1981; 10(9):462-7. [88] Eze UA, Nathaniel GI, Pepple G. Ophthalmic uses of atropine: a review. J Adv Med Med Res. 2022; 34(22):197-205. [89] Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2003; 74(1):1-4. [90] Ishijima T, Koshino H, Hirai T, Takasaki H. The relationship between salivary secretion rate and masticatory efficiency. Journal of oral rehabilitation. 2004;31(1):3-6. [91] Henderson VE, Roepke MH. On the mechanism of salivary secretion. The Journal of Pharmacology and Experimental Therapeutics. 1933;47(2):193-207. [92] Lidums I, Hebbard GS, Holloway RH. Effect of atropine on proximal gastric motor and sensory function in normal subjects. Gut. 2000; 47(1):30-6. [93] Mittal RK, Chiareli C, Liu J, Holloway RH, Dixon W. Atropine inhibits gastric distension and pharyngeal receptor mediated lower oesophageal sphincter relaxation. Gut. 1997; 41(3):285-90. [94] Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug safety. 2008; 31:373-88. [95] Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstetrics & Gynecology. 2008 Dec 1; 112(6):1311-8. [96] Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of internal medicine. 2008 10; 168(5):508-13. [97] Yayla EM, Yavuz E, Bilge U?, Keskin AH, Binen E. Drugs with anticholinergic side-effects in primary care. Nigerian journal of clinical practice. 2015;18(1):18-21 [98] Cilag J, Abbott E, Center G. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001; 62(21):11-4. [99] C?kla U, Turkmen S, Karaca Y, Ayaz AF, Turedi S, Gunduz A. An Atropa belladonna L. poisoning with acute subdural hematoma. Human & experimental toxicology. 2011; 30(12):1998-2001. [100] Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine. 1983; 13(3):513-27.

Copyright

Copyright © 2025 Suman Mondal, Somenath Bhattacharya, Soumallya Chakraborty. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.